Filing summary
Entity and period: The supplied filing is CopyTele, Inc.’s unaudited Form 10-Q for the quarter ended July 31, 2012—not an Anixa Biosciences filing. It reports the three- and nine-month periods ended July 31, 2012, compared with the same periods in 2011. CopyTele developed display technologies and encryption products.
Financial performance
| Metric | Three months ended July 31 | Nine months ended July 31 |
|---|---|---|
| Revenue, 2012 / 2011 | $249,470 / $450,360 | $946,735 / $554,233 |
| Operating loss, 2012 / 2011 | $643,338 / $1,207,658 | $2,408,792 / $4,021,350 |
| Net loss, 2012 / 2011 | $629,102 / $1,773,498 | $2,392,296 / $4,586,647 |
| Basic and diluted loss per share | $0.00 / $(0.01) | $(0.01) / $(0.03) |
- Nine-month revenue was primarily AUO display-technology license revenue: $940,010, versus $426,000 a year earlier. Encryption-product sales fell to $6,725 from $128,233.
- Quarterly revenue declined as AUO license revenue fell to $246,670 from $426,000; encryption revenue was $2,800 versus $24,360.
- Nine-month R&D expense declined to $1.712 million from $2.388 million; SG&A declined to $1.641 million from $2.154 million. Lower compensation, stock-based expenses, and development activity contributed to the reductions.
- Cash used in operations was $2.178 million for the nine months, versus $3,510 in the prior-year period. Cash and cash equivalents were $101,532; short-term investments were $950,000. Together these totaled approximately $1.052 million, down from $3.023 million at October 31, 2011.
- Working capital deteriorated from approximately $1.015 million positive to $636,000 negative. Total assets were $5.887 million; shareholders’ equity was a deficit of $893,071.
- A $5 million related-party loan payable remained outstanding, due December 2014, with a corresponding $5 million related-party loan receivable shown as a contra-equity item. The filing also reports $730,000 in operating lease obligations.
Changes, outlook, and risks
- Management stated that existing resources and anticipated cash flows would not fund planned operations for 12 months from the reporting-period end, and disclosed substantial doubt about the company’s ability to continue as a going concern. It had no additional financing arrangements in place and warned that failure to secure funding or reduce expenses could require curtailing or ceasing operations.
- After quarter-end, CopyTele raised $750,000 gross through 8% convertible debentures due September 12, 2016, convertible at $0.092 per share. Full conversion would issue approximately 8.15 million shares. The company warned that the beneficial conversion feature would cause a material expense in fiscal Q4 2012. Some debentures were purchased by the CEO and a director.
- Up to $7 million in further AUO license fees was conditional on completion of specified conditions; management could not estimate whether or when it would be received. CopyTele suspended recognition of revenue for certain technology while reassessing its performance period. AUO royalties had not been recognized.
- Videocon had paid $3.2 million of a scheduled $11 million license fee; no payments were received in the current or prior-year nine-month periods. Management was discussing the remaining balance but could not estimate the outcome. The company reported no current development work with Videocon.
- One customer represented 99.3% of total nine-month revenue. The Videocon investment was carried at $4.603 million after a $779,334 unrealized loss during the period; a hypothetical 10% adverse move in share price and exchange rates was estimated to reduce fair value by approximately $460,000.
- Management was reviewing its patent portfolio, business relationships, and development programs, and had reduced activity with Volga. It also said it discontinued issuing stock to employees and consultants as compensation after July 31. No material litigation was reported; management said disclosure controls were effective and identified no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: the provided filing names CopyTele, Inc., not Anixa Biosciences Inc.
- Assess near-term liquidity and financing needs, including the effect and dilution potential of the September debentures.
- Track whether AUO’s remaining conditional fees become payable, when deferred revenue recognition resumes, and whether royalties or product sales develop.
- Verify progress on collecting Videocon’s unpaid license fees and monitor the market and currency exposure of the Videocon investment.
- Evaluate whether expense reductions and reduced development activity affect the company’s ability to commercialize its technologies and maintain operations.